Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
@rforno ,thanks for the reminder. @ep1 Type in - hqh- in this site's search box for some fellow poster's reviews and discussions concerning bio/health including @scott who usually gave us pertinent info on some long term investment ideas. From just over a year ago, "Why not HQL? Just sit back and collect the div. Can also invest in private companies." Thanks @scott. I had forgotten about that one. Definitely worth a look.
CNCR Smaller fund to watch with this initiative? The Obama administration has launched a "moonshot" to cure cancer. What are the chances of success? Here's everything you need to know: http://theweek.com/articles/623940/new-war-cancer
I like SBIO and PBE for biotech. IBB is a decent fund but just a few big names take up a large portion of assets, mainly the big 4 biotech companies. That comes across to me as a red flag of sorts.
THQ is a bit of an odd-ball in Tekla's line-up of four health funds. Goal is more income than capital appreciation. I'm not sure why its discount has been so high, but it has come down. HQH and HQL do not have appreciable discount or premiums these days. Their distribution policies have worked well for investors (et moi…).
Comments
PRHSX has a healthy slug of biotech, as do many other health-science type mutual funds.
2. T. Rowe Price Health Sciences Fund: (PRHSX)
3 . Janus Global Life Sciences Fund: (JAGLX)
4. Franklin Biotechnology Discovery Fund: (FBDIX)
5. IShares NASDAQ Biotechnology Index: (IBB
Regards,
Ted
@ep1
Type in - hqh- in this site's search box for some fellow poster's reviews and discussions concerning bio/health including @scott who usually gave us pertinent info on some long term investment ideas.
From just over a year ago,
"Why not HQL? Just sit back and collect the div. Can also invest in private companies."
Thanks @scott. I had forgotten about that one. Definitely worth a look.
CNCR
Smaller fund to watch with this initiative?
The Obama administration has launched a "moonshot" to cure cancer. What are the chances of success? Here's everything you need to know:
http://theweek.com/articles/623940/new-war-cancer
http://www.etf.com/CNCR
http://www.etf.com/sections/features-and-news/cancer-etf-redefines-biotech-investing?nopaging=1
I own ETNHX in this space. ETNHX 3 YR Standard Deviation 30.75 Like most in Bio,Volitile!
From Fact Sheet:
Industry Allocation‡ % of portfolio
Biotech 68.54
Pharmaceuticals 13.10
Healthcare Tech. 6.60
Healthcare Equip. 4.82
Other (cash ) 7.00
http://eventidefunds.com/wp-content/uploads/Eventide-Healthcare-Life-Sciences-Fund-Fact-Sheet-06-30-2016.pdf
On the debt side, do your due diligence here.I own HTGC ,mostly for the dividend ( re-invested ). Caution, trading above book.
http://www.htgc.com/portfoliolisting.asp?SectorID=5